http://www.narcis.nl/publication/RecordID/oai:pure.rug.nl:publications%2F661e6d46-d085-4a85-a214-7f400e9a8c8d
| Published in | Pharmaceutics, Vol. 6, No. 4, p.557-83. |
|---|---|
| Author | Zuhorn, Inge; Georgieva, Julia V.; Hoekstra, Dick |
| Publisher | Center for Liver, Digestive and Metabolic Diseases (CLDM); Nanobiotechnology and Advanced Therapeutic Materials (NANOBIOMAT); Molecular Neuroscience and Ageing Research (MOLAR) |
| Date | 2015 |
| Language | English |
| Type | Article |
| Abstract | The blood-brain barrier acts as a physical barrier that prevents free entry of blood-derived substances, including those intended for therapeutic applications. The development of molecular Trojan horses is a promising drug targeting technology that allows for non-invasive delivery of therapeutics into the brain. This concept relies on the application of natural or genetically engineered proteins or small peptides, capable of specifically ferrying a drug-payload that is either directly coupled or encapsulated in an appropriate nanocarrier, across the blood-brain barrier via receptor-mediated transcytosis. Specifically, in this process the nanocarrier-drug system ("Trojan horse complex") is transported transcellularly across the brain endothelium, from the blood to the brain interface, essentially trailed by a native receptor. Naturally, only certain properties would favor a receptor to serve as a transporter for nanocarriers, coated with appropriate ligands. Here we briefly discuss brain microvascular endothelial receptors that have been explored until now, highlighting molecular features that govern the efficiency of nanocarrier-mediated drug delivery into the brain. |
| Publication | https://www.rug.nl/research/portal/en/publications/smuggling... |
No comments:
Post a Comment